TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05439083

Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: 9-valent HPV vaccine
Description: All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 9-valent HPV vaccine
Description: All participants will receive the immunization schedule according to guidelines: immunosuppressed patients will receive a three-dose schedule: 0.5 mL intramuscular injection of 9vHPV at entry plus an additional dose at month 2 and month 6. Healthy controls aged 9-14 years will receive a two-dose schedule: 0 and 6 months.
Study: NCT06359639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring
Description: Five 50-60-minute videoconferencing sessions of cognitive restructuring based on Mind Over Mood: Second Edition (MOM2) (Greenberger \& Padesky, 2016) and The Clinician's Guide to CBT Using MOM2 (Padesky \& Greenberger, 2019) as guides. The sessions will consist of understanding the cognitive model, filling in Thought Records, and complementary coping strategies of looking for evidence, action planning, and acceptance.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supportive counselling
Description: Five 50-60-minute videoconferencing sessions of supportive counselling consisting of psychoeducation on breakup effects, validation of breakup experiences and emotions, introduction to deep breathing and progressive muscle relaxation, and identification of existing coping strategies.
Study: NCT04283604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPH
Description: The treatment will include taking the patient's own medication by the patient himself in the treatment session 60-180 minutes before the beginning of the tests, according to their prescription given by their own physician. Participants must have consumed this medication at least 3 months before the first session as their regular treatment for ADHD. Note, we are not planning on giving the medication to the participant, rather he/she will consume their own prescribed MPH by them self.
Study: NCT05360485

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MOV'D (Move Often eVery Day)
Description: The MOV'D intervention is a remotely-delivered, peer-supported intervention that delivers exercise snack (2-5 minutes of moderate to vigorous activity) and behavior change technique (BCT) videos to a private social media support group with the goal of interrupting prolonged sitting at work with MVPA minutes.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit Self-Monitoring
Description: All participants receive a Fitbit and are told to monitor their physical activity for the duration of the study period.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Fitbit Self-Monitoring
Description: All participants receive a Fitbit and are told to monitor their physical activity for the duration of the study period.
Study: NCT06626295

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: exercise-snack group
Description: Adolescents in the exercise-snacks group will perform 4 \&amp;amp;amp;#34;exercise-snacks\&amp;amp;amp;#34; sessions per day during 3 weeks in addition to multidimensional care program. These sessions will consist of 1-min various intense supervised exercises . They will also receive information about their attitudes to physical activity.
Study: NCT05326581

Intervention type: DEVICE
Intervention: mri
Description: The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.

Intervention type: DEVICE
Intervention: mri
Description: The people included will carry out an MRI comprising the sequence currently used in routine care and the different variants of the sequence being tested, for the optimization of the parameters. The duration of the examination (or the extension of the examination planned as part of patient care) will be from a few minutes to an hour depending on the sequences to be optimized. Subjects who agree to research for more than 30 minutes in the MRI machine will be compensated with a multi-brand gift voucher worth 30 euros.
Study: NCT06127043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosnilimab
Description: PD-1 agonist antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosnilimab
Description: PD-1 agonist antibody

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered via SC
Study: NCT04481802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RadiaAce gel
Description: Patients will apply the RadiaAce to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biafine
Description: Patients will apply the Biafine to the treatment area starting 5 days before radiation treatment. The Hydrogel/cream will be applied three times a day with a minimum of four hours between applications. Treatments will be used through the course of RT and for 6 days after the last fraction of radiation.
Study: NCT06148311

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching placebo
Description: One matching placebo will be given under the tongue on a thin dissolvable film.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine 120 mcg will be given under the tongue on a thin dissolvable film.
Study: NCT05287529

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Via Telehealth - Immediately
Description: The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Yoga Via Telehealth - Waitlisted
Description: The yoga program is an in-home, chair-assisted yoga class focused on balance. Each class will be led by a certified yoga teacher who has completed training the the yoga for Seniors Program. Classes will consist of no more than 12 participants. Each class will be attended by a local community member who will facilitate community building before and after class and will be available to activate local emergency medical services in the unlikely event that the need arises. Classes are 75 minutes in duration and meet two times per week.
Study: NCT06619626

Intervention type: DEVICE
Intervention: alveolar recruitment strategy applied group
Description: the effect of alveolar recruitment strategy on the mechanical parameters of the patients

Intervention type: DEVICE
Intervention: alveolar recruitment strategy applied group
Description: the effect of alveolar recruitment strategy on the mechanical parameters of the patients

Intervention type: DRUG
Intervention: group without alveolar recruitment strategy
Description: effect on mechanical parameters of patients without alveolar recruitment strategy

Intervention type: DRUG
Intervention: group without alveolar recruitment strategy
Description: effect on mechanical parameters of patients without alveolar recruitment strategy
Study: NCT05325216

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: POPRC+OIN
Description: Pelvic-organ preserving radical cystectomy with orthotopic ileal neobladder

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: SRC+OIN
Description: Standard radical cystectomy with orthotopic ileal neobladder
Study: NCT06385093

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eldecalcitol capsules
Description: Oral eldecalcitol 0.75μg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Alfacalcidol tablets
Description: Oral Alfacalcidol 0.5μg daily

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Calcium carbonate tablets
Description: 1.5g Calcium carbonate daily
Study: NCT04819230

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Bias Modification
Description: A four-week computerized attentional and interpretive bias modification protocol in which participants complete both ATT and ITT tasks twice per week, totaling to eight experimental sessions (see experimental arm for more detail.)

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Cognitive Bias Control
Description: A four-week computerized attentional and interpretive stimuli protocol in which participants complete both ATT-C and ITT-C tasks twice per week, totaling to eight control sessions (see placebo control arm for more detail.)
Study: NCT06344910

Intervention type: OTHER
Intervention: Best practice alert for the notification of patients with HFrEF and recommended evidence-based therapies
Description: An algorithm will check if the patients if the patient has an age \>18 year and is treated at the cardiology department for HFrEF. The use of GDMT is determined using prescriptions data electronic health records (EHR). If the patient does not receive treatment for all 4 drug classes (ACE/ARB/ARNi, beta-blocker, MRA, SGLT2-inhibitor), an electronic alert will be displayed suggesting the clinician to prescribe additional medication when clinically indicated, including relevant recent laboratory results (renal function and electrolytes) and other relevant measures (LVEF, blood pressure and heart rate). The alert is linked to an order set to aid in the prescription of GDMT according to current guidelines.~Results will compared to a retrospective cohort (t=-12 to t=-6) months, and a silent mode cohort (t=-6 to t=0 months, in which a paired and a before and after analysis will be performed to evaluate the effect of the alert.
Study: NCT06426368

Intervention type: DIAGNOSTIC_TEST
Intervention: ST2
Description: ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure

Intervention type: DIAGNOSTIC_TEST
Intervention: ST2
Description: ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure

Intervention type: DIAGNOSTIC_TEST
Intervention: ST2
Description: ELISA used to detect levels of ST2 and BNP as inflammatory biomarkers in patients with heart failure
Study: NCT05489627

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement
Description: Medial knee instabilities will be addressed in this arm as described in the published technique: K. Malinowski, K. Hermanowicz, A. Góralczyk, R.F. LaPrade, Medial Collateral Ligament Reconstruction With Anteromedial Reinforcement for Medial and Anteromedial Rotatory Instability of the Knee, Arthrosc. Tech. 8 (2019) e807-e814. https://doi.org/10.1016/j.eats.2019.03.019.~Due to the fact that isolated injury of medial stabilizers of the knees is very rare, included will be patients with concomitant ACL QTB reconstruction and abovedescribed MCL reconstruction. Any accompanying intraarticular injuries such as meniscal lesions will be addressed as well.
Study: NCT04688827

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: 15 weeks of resistance training (additional to endurance training)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise therapy
Description: 15 weeks of resistance training (additional to endurance training)
Study: NCT05532072

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Rapamycin plus Methylprednisolone

Intervention type: DRUG
Group type: OTHER
Intervention: Methylprednisolone
Description: Methylprednisolone Alone

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: Methylprednisolone Alone
Study: NCT06136754

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Varnishes, Fluoride
Description: Fluoride varnish containing 5.0% NaF

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Varnishes, Fluoride
Description: Fluoride varnish containing 5.0% NaF
Study: NCT05885984

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Acceptance and Commitment Therapy (ACT) plus health education
Description: Session 1: Reviewing experiences on struggles with CRF, realising consequence of controlling, introducing acceptance as an alternative, adopting virtual mindfulness. Education (patient): epidemiologic features of advanced lung cancer. Session 2: Separate thoughts/feelings related to CRF. Education (patient): treatments and symptoms of advanced lung cancer. Session 3: Reviewing caregiver's experiences of struggling with caregiving burden,introducing acceptance as an alternative. Education (caregiver): epidemiologic features of advanced lung cancer. Session 4: Separate caregivers' thoughts/feelings related to caregiving burden. Education (caregiver): treatments and symptoms of advanced lung cancer. Session 5:Understand the importance of values and clarifying personal values for dyads. Education (dyads): eating suggestions. Session 6: Emphasise ongoing value-based goals and commitment to actions for a meaningful cancer life for dyads. Education (dyads): exercising suggestions.

Intervention type: OTHER
Group type: OTHER
Intervention: Health education
Description: Session 1: health education on the epidemiologic features of advanced lung cancer will be taught to patients. Session 2: health education on treatments and related symptoms of advanced lung cancer will be taught to patients. Session 3: health education on the epidemiologic features of advanced lung cancer will be taught to caregivers. Session 4: health education on treatments and related symptoms of advanced lung cancer will be taught to caregivers. Session 5: health education on eating suggestions for advanced lung cancer patients and caregivers will be taught. Session 6: health education on exercising suggestions for advanced lung cancer patients and caregivers will be taught.
Study: NCT05890131

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital letter
Description: A digital letter with evidence-based information about the newly approved heart failure therapy option, SGLT-2 inhibitors. The letter will also invite recipients to be evaluated by a heart failure specialist for potential initiation of the therapy.
Study: NCT06706362

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bactrim or Macrobid
Description: Participants will be assigned to Bactrim or Macrobid depending on participants' allergies

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will be assigned to identical appearing placebo
Study: NCT06732804

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AVT80
Description: Single subcutaneous injection of AVT80 (108mg)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Geographical region 1 Entyvio
Description: Single subcutaneous injection of Geographical region 1 Entyvio (108mg)

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Geographical region 2 Entyvio
Description: Single subcutaneous injection of Geographical region 2 Entyvio (108mg)
Study: NCT06756256

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Customized insole
Description: Participants will wear the produced customized insoles during daily activities and interventions for six weeks under the guidance of physical therapists working at Miso Hospital in Iksan City. As their continuation of their rehabilitation program, they will receive a conservative physiotherapy treatment five times a week for six weeks.
Study: NCT06778902

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: azacytidine
Description: Azacytidine: 75mg/m2, d1-d5

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: R-GemOx
Description: Rituximab: 375mg/m2, d6; Gemcitabine: 1g/m2, d7 Oxaliplatin: 100mg/m2, d7
Study: NCT06778434

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Description: 10% imipramine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Imipramine
Description: 10% imipramine

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Vehicle
Description: polyethylene glycol: dimethyl sulfoxide Solution

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control Vehicle
Description: polyethylene glycol: dimethyl sulfoxide Solution
Study: NCT05331703

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed physical therapy program in addition to program of virtual reality.
Description: physical therapy program in addition to program of virtual reality.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: designed physical therapy program in addition to program of mirror therapy.
Description: physical therapy program in addition to program of mirror therapy.
Study: NCT04976218

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TGFβR-KO CAR-EGFR T Cells
Description: Enrolled patients will be administered TGFβR-KO CAR-EGFR T Cells in 3+3 based escalation manner. The infused CAR+ T cell dose in phase IA will be started initially at 1-2×10\^5/kg, dose 2 will be 1×10\^6/kg，and dose 3 will be 1×10\^7/kg, if DLT occurs in dose level 3, the following dose will return to 5×10\^6/kg. In expansion period, the dose of infused CAR+ T cells will be determined by the recommended cell dose from phase IA.
Study: NCT06208189

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High-effort session
Description: Participants will perform 3 sets per exercise (total of 21 sets) with as many repetitions they can each set. We anticipate participants will perform \~10 repetitions per set in this session, with a total tempo of \~2.5 seconds per rep, averaging \~25 seconds per set. Resting period between exercises and sets will be 120 seconds. This will lead to a total session time of \~50 min. Their glycemic control will be evaluated during the following \~48 hours.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low-effort session
Description: Participants will perform 6 sets per exercise (total of 42 sets) but perform half of the anticipated number of repetitions of the HIGH session (i.e., 5 reps). Repetition tempo at \~2.5 seconds will result in \~12.5 seconds per set. Resting period between exercises and sets will be 60 seconds. This prescription will also lead to a total session time of \~50 min. Thus, both the HIGH and LOW session will have similar total volume-load and session density, but differ in perceived effort after each set. Their glycemic control will be evaluated during the following \~48 hours.

Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Control
Description: The control session all procedures will be identical to the HIGH session, with the exception of performing the resistance exercises. However, to simulate all other procedures participants will follow all instructions, be positioned on the equipment for the same amount of time as the HIGH session, but will not perform any repetition. Interval between fake sets and exercises will be 120 seconds. Their glycemic control will be evaluated during the following \~48 hours.
Study: NCT05785507

Intervention type: OTHER
Intervention: PriskA tool
Description: PriskA tool is an algorithm that generates a risk score of having PCOS.

Intervention type: OTHER
Intervention: PriskA tool
Description: PriskA tool is an algorithm that generates a risk score of having PCOS.
Study: NCT05732961

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Luspatercept
Description: Participants will be treated with Luspatercept, with a starting dose of 1.0 mg/kg subcutaneous injection every 3 weeks (administered on Day 1 of each 21-day treatment cycle)
Study: NCT04027270

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Therapy
Description: Physical therapy 1-2 times per week for 3 months postoperatively to include lifestyle education, manual therapy, and exercise.
Study: NCT06491290

Intervention type: OTHER
Intervention: No intervention administered
Description: NA (not applicable)
Study: NCT05123703

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ocrelizumab
Description: Ocrelizumab 300 milligrams (mg) will be administered by IV infusion to participants who weigh \< 35 kilograms (kg) and ocrelizumab 600 mg IV will be administered to participants who weigh ≥ 35 kg on Days 1 and 15 (half the dose, 2 weeks apart) and Q24W thereafter.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ocrelizumab Placebo
Description: Ocrelizumab matching placebo will be administered by IV infusion on Day 1 and Day 15 and Q24W thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fingolimod
Description: Fingolimod will be administered daily as a capsule per the prescribing information (0.25 mg to participants who weigh ≤ 40 kg and 0.5 mg to participants who weigh \> 40 kg).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fingolimod Placebo
Description: Fingolimod matching placebo will be administered daily as a capsule.
Study: NCT04704427

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Non-invasive BCI training
Description: In the experimental group, the participants receive non-invasive rehabilitative BCI training. The training using the lower limb orthosis targeted the patient's ability to walk.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Physiotherapy protocol
Description: In the control group，the participants receive the traditional physiotherapy protocol, including muscle strength training, balance training and walking training, etc.